Preclinical Development

Rb–Raf-1 Interaction Disruptor RRD-251 Induces Apoptosis in Metastatic Melanoma Cells and Synergizes with Dacarbazine

Sandeep Singh, Rebecca Davis, Vignesh Alamanda, Roberta Pireddu, Daniel Pernazza, Said Sebti, Nicholas Lawrence, and Srikumar Chellappan

Abstract

Metastatic melanoma is an aggressive cancer with very low response rate against conventional chemotherapeutic agents such as dacarbazine (DTIC). Inhibitor of Rb–Raf-1 interaction RRD-251 was tested against the melanoma cell lines SK-MEL-28, SK-MEL-5, and SK-MEL-2. RRD-251 was found to be a potent inhibitor of melanoma cell proliferation, irrespective of V600E B-Raf mutation status of the cell lines. In a SK-MEL-28 xenograft experiment, RRD-251 exerted a significant suppression of tumor growth compared with vehicle (P = 0.003). Similar to in vitro effects, tumors from RRD-251–treated animals showed decreased Rb–Raf-1 interaction in vivo. Growth suppressive effects of RRD-251 were associated with induction of apoptosis as well as a G1 arrest, with an accompanying decrease in S-phase cells. RRD-251 inhibited Rb phosphorylation and downregulated E2F1 protein levels in these cells. Real-time PCR analysis showed that RRD-251 caused downregulation of cell-cycle regulatory genes thymidylate synthase (TS) and cdc6 as well as the antiapoptotic gene Mcl-1. Combinatorial treatment of RRD-251 and DTIC resulted in a significantly higher apoptosis in DTIC resistant cell lines SK-MEL-28 and SK-MEL-5, as revealed by increased caspase-3 activity and PARP cleavage. Because aberrant Rb/E2F pathway is associated with melanoma progression and resistance to apoptosis, these results suggest that the Rb–Raf-1 inhibitor could be an effective agent for melanoma treatment, either alone or in combination with DTIC.

Introduction

The incidence of melanoma is continuously rising and has increased more than 6-fold over the past 50 years (1, 2). Melanoma is highly resistant to the conventional chemotherapeutic agent dacarbazine (DTIC) and has a response rate of only 15% to 20% with the median response duration of only 4 months (3–5). In addition, the new treatments have also failed to significantly improve the survival time (6–8). Thus, it is essential to identify new therapeutic targets for better treatment of the disease.

Several studies have suggested that in human melanoma cells all 3 Rb family pocket proteins (pRb, p107, and p130) are hyperphosphorylated and several E2F family members (E2F1, E2F2, E2F3, and E2F4) are present in unbound, transcriptionally active forms (9–13). The retinoblastoma tumor suppressor protein, Rb, plays a vital role in regulating mammalian cell proliferation primarily by its interaction with the E2F family of transcription factors (14, 15). Rb binds to E2Fs 1, 2, and 3 and suppresses their transcriptional activity, inhibiting their ability to drive the expression of proliferative promoters (16, 17). In response to mitogenic signals, Rb is hyperphosphorylated through a cascade of phosphorylation events, which leads to its inactivation and dissociation from E2Fs. Free E2Fs can actively participate in the transcription of target genes such as cdc6 and thymidylate synthase (TS), facilitating S-phase entry and cell-cycle progression (17).

Several kinases can phosphorylate Rb. For example, cyclin-dependent kinases (CDK) such as CDK4 and CDK2 phosphorylate Rb and this is essential for the G1 to S phase transition (18). Recently, we had shown that the signaling kinase Raf-1 can physically bind and phosphorylate Rb very early in the cell cycle, facilitating its further hyperphosphorylation by CDKs and eventual inactivation (19, 20). We have previously reported that the disruption of Rb–Raf-1 interaction by an 8-amino acid peptide (corresponding to Raf-1 residues 10–18) prevented Rb phosphorylation even in the later stages of
This suggests that preventing the binding of Raf-1 to Rb keeps Rb in a functional, hypophosphorylated form with its tumor suppressor role intact (20). Our attempts to identify a small molecule disruptor of Rb–Raf-1 interaction resulted in the characterization of RRD-251, which had potent antiproliferative, antiangiogenic, and antitumor activity against non–small cell lung carcinoma cells in vitro and in vivo (21). Here we have explored the efficacy of RRD-251 in targeting melanoma cells SK-MEL-28, SK-MEL-5, and SK-MEL-2.

We find that RRD-251 can inhibit the growth of melanoma cells by induction of apoptosis as well as cell-cycle arrest. We further show that pretreatment of cells with DTIC enhanced the proapoptotic effects of RRD-251 on these cells. Overall, these data suggest that RRD-251 possesses potent anticancer activity against melanoma in vitro and in vivo. Furthermore, it appears that the combination of DTIC and RRD-251 would be a viable strategy to combat the growth and progression of melanoma.

Materials and Methods

Cell lines and reagents

The metastatic melanoma cell lines, SK-MEL-28, SK-MEL-5, and SK-MEL-2 were purchased from ATCC and cultured in MEM containing 10% fetal bovine serum (FBS; Mediatech) and maintained in 5% CO₂ at 37°C. Although these cell lines were originally purchased from ATCC, we did not revalidate them. DTIC was obtained from Sigma and 100 mmol/L of stock solution was prepared by dissolving the drug in dimethyl sulfoxide (DMSO). RRD-251 was synthesized by our in-house chemistry laboratory. It is a benzyl-isothiourea compound with chloride as the counter ion (19). The chemical structures of RRD-251 and DTIC are shown in Supplementary Fig. S1. Unless not indicated, cells were treated with 50 μmol/L concentration of DTIC and RRD-251. Primary antibodies against PARP and caspase-3 were obtained from Cell Signaling Technology; Rb and Raf-1 by immunoprecipitation–Western blot experiments using Vindelov method and cell-cycle analysis was done by flow cytometry (22).

Proliferation and soft agar colony-formation assay

Actively growing human melanoma cells were plated in 96-well plates at a density of 7,500 cells per well in triplicates. After 24 hours, cells were treated with 20 and 50 μmol/L concentrations of RRD-251 or the solvent (DMSO). Cell proliferation assay was carried out with the 1 mg/mL MTT solution at 37°C for 1 hour. The reaction was terminated with DMSO that stained with MTT (1 mg/mL) for 1 hour at 37°C. Experiment was repeated twice in duplicate.

In vivo xenograft experiments in nude mice

SK-MEL-28 cells were harvested in PBS and mixed with equal volume of matrigel (BD Biosciences) and implanted subcutaneously into the right and left flanks (10 × 10⁶ cells per flank) of 8-week-old female athymic nude mice (Charles River) as described previously (21). When xenograft tumor growth was established, treatment by intraperitoneal injection of 0.1 mL of the drug or the vehicle was initiated. Tumor volumes were determined by measuring the length (L) and the width (W), and calculating the volume (V = L × W²/2). Statistical significance between control and treated animals were evaluated using Student’s t test.

Cell-cycle analysis by flow cytometry

Cells were treated with indicated dose of RRD-251 for given time. Following treatment, cells were scrapped and collected. Cell pellet was washed in PBS and resuspended in 0.1 mL of citrate/DMSO buffer (250 mmol/L sucrose, 40 mmol/L Na₂C₆H₅O₇·2H₂O, 5% DMSO, pH 7.6). The pellets were then frozen at −80°C. Samples were processed as suggested in Vindelov method and cell-cycle analysis was done by flow cytometry (22).

Lysate preparation, immunoprecipitation, and Western blotting

Cell lysates were prepared by lysis-buffer containing NP40, as described earlier (20, 21). Tumor lysates were prepared with T-Per tissue lysis buffer (Pierce) and a Fisher PowerGen 125 dounce homogenizer (21). Physical interaction between proteins in the tumors was analyzed by immunoprecipitation–Western blot experiments using 200 μg of lysate and 1 μg of the indicated antibody (20).

Real-time PCR

Melanoma cells were treated with RRD-251 for indicated time. DMSO-treated cells were used as vehicle control. Total RNA was isolated by an RNAeasy miniprep kit from QIAGEN following the manufacturer’s protocol. One microgram of RNA was used for first-strand cDNA synthesis using the iScript cDNA synthesis kit (Bio-Rad). A fraction (1/20) of the final cDNA reaction volume was used in each PCR. Primer sequences are as follows: 5'-CTG CCA GCT GTA CCA GAG AT-3' (TS forward primer), 5'-ATG TGC ATC TCC CAA AGT GT-3' (TS reverse primer), 5'-CCC CAT GAT TGT GGT GGT AT-3' (cdc6 forward primer), 5'-TTC AAC AGC TGT GGC TAA CA-3' (cdc6 reverse primer), 5'-ATG TCT CGG AAA CTG GAC AT-3' (Mcl-1 forward primer), 5'-TCC TGA TGC CAC CTT CTA GG-3' (Mcl-1 reverse primer), 5'-CTC AAC ACG GGA AAC CTC AC-3' (18S forward primer), and
5'-AAA TCG CTC CAC CAA CTA AGA A-3' (185 reverse primer). Real-time PCR was done on a Bio-Rad iCycler and analyzed by ddCt method.

**Caspase-3/7 activity assay and TUNEL assay**

Cells were grown in 8-well chamber slides and treated with RRD-251 for 24 hours. Terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining was done using DeadEnd TUNEL Assay kit (Promega), per the manufacturer's instructions. Actively growing melanoma cells were plated in clear bottom 96-well plates at a density of 7,500 cells per well in triplicates. After 24 hours, cells were treated with 50 μmol/L concentrations of DTIC or the solvent (DMSO). Forty-eight hours post-DTIC treatment, RRD-251 was added in the respective wells and further incubated for 4 hours. Caspase activity were measured by quantitative luminescence assays using caspase-3/7–activatable DEVD-aminoluciferin (Caspase-Glo 3/7 kit, Promega). Assays were done according to the manufacturer’s protocol and plates were read in a luminometer (Perkin Elmer).

**Comet assay**

The comet assay was done in its alkaline version following published protocols (23, 24). Cells were treated with 50 μmol/L DTIC for 48 hours. After treatment, the cells were mixed with 0.8% (w/v) low melting point agarose and the mixture spread onto 2 slides precoated with 1.5% (w/v) normal melting point agarose. The slides were covered with coverslips and were refrigerated for 60 minutes at 4°C. Subsequently, the slides were placed in an alkaline buffer (1 mmol/L Tris-HCl (pH 10) containing 1% (v/v) Triton X-100) for 60 minutes at 4°C. Then, the slides were washed in an alkaline buffer (1 mmol/L of EDTA, 300 mmol/L of NaOH, pH > 13) for 20 minutes at 4°C for the DNA to unwind. For electrophoresis, slides were equilibrated in 1X TBE for 10 minutes following electrophoresis in the same buffer at 0.52 V/cm for 5 minutes. Slides were washed in water, dried at room temperature, and fixed in 100% ethanol for 5 minutes. The slides were stained with 80 μL of 2 μg/mL ethidium bromide and rinsed with water. Randomly selected cells from each sample and %DNA damage was analyzed using LAI Automated Comet Assay Analysis System (Loats Associates Inc.).

Results

**In vitro and in vivo antimelanoma effects of RRD-251**

Melanoma cells harbor persistently hyperphosphorylated Rb proteins and this appears to be associated with melanoma progression and resistance to apoptosis. We, therefore, investigated the effects of Rb-Raf-1 disruptor RRD-251 on melanoma tumors. As a first step, the effect of RRD-251 on cell survival and anchorage-dependent cell growth was tested by a MTT assay. SK-MEL-28, SK-MEL-5, and SK-MEL-2 cells were grown in the absence or presence of increasing concentrations (10, 20, and 50 μmol/L) of RRD-251 for 24 hours. RRD-251 treatment resulted in a dose-dependent decrease in cell survival in all the 3 cell lines (Fig. 1A). The IC_{50} value for SK-MEL-28, SK-MEL-5 (both carrying a V600E mutant B-Raf), and SK-MEL-2 (carrying wild-type B-Raf) were found to be 28.7 μmol/L, 37.3 μmol/L, and 48 μmol/L, respectively. Next, the effect of RRD-251 on the anchorage-independent growth of these cell lines in soft agar was examined. As shown in Fig. 1B, RRD-251 could significantly suppress anchorage-independent colony formation of SK-MEL-28, SK-MEL-5, and SK-MEL-2 cells in a dose-dependent manner. These data show that RRD-251 treatment produces strong inhibition of viability and proliferation of melanoma cells, irrespective of their B-Raf status.

Given the ability of RRD-251 to exert antiproliferative effects in cultured cells, we next examined whether RRD-251 could inhibit tumor growth in vivo in nude mouse xenograft models. SK-MEL-28 cells mixed with matrigel were implanted by subcutaneous injection in nude mice, and the tumors were allowed to reach an average size of 376 mm³ in size before intraperitoneal administration of RRD-251 or vehicle. As shown in Fig. 1C, tumors from vehicle-treated mice grew to an average size of 733 ± 86 mm³. In contrast, tumors did not grow significantly (average tumor size at the end of treatment was 362 ± 34 mm³) in mice treated with RRD-251. This antitumor effect of RRD-251 was statistically significant after 9 days of treatment and remained significant throughout the duration of the experimental period. The body weight of vehicle- or RRD-251–treated mice were not affected (Fig. 1D). This set of experiments suggests that RRD-251 has anticancer activities in vitro and in vivo on melanomas.

**RRD-251 inhibits Rb–Raf-1 interaction and Rb phosphorylation**

Previous studies from our laboratory had shown that RRD-251 inhibits Rb–Raf-1 interaction and Rb phosphorylation in non–small cell lung cancer cells (20, 21). Here, we extended our study to check the effects of RRD-251 on Rb phosphorylation in melanoma cells having different B-Raf (V600E) mutation status. SK-MEL-28 and SK-MEL-5 cells with mutant B-Raf as well as SK-MEL-2 cells with wild-type B-Raf were treated with 50 μmol/L RRD-251 for 2 hours. Phosphorylation of Rb was ascertained by Western blotting. As shown in Fig. 2A, treatment with RRD-251 resulted in reduced Rb phosphorylation in all the 3 cell lines; there was a slight reduction in the levels of Rb protein as well. To examine whether RRD-251 inhibits Rb phosphorylation because of the disruption of the physical association of Raf-1 with Rb (21), we immuno-precipitated Raf-1 from lysates prepared from RRD-251–treated or untreated cells and Rb was detected by Western blotting. Figure 2B shows that the binding of
Raf-1 to Rb was inhibited by RRD-251 in both B-Raf wild-type (SK-MEL-2) and mutant (SK-MEL-28) cells. Overall, these results suggest that RRD-251 disrupts Rb–Raf-1 association and inhibits Rb phosphorylation, irrespective of B-Raf mutation status in melanoma cells. Next, to assess whether RRD-251 affected its target in vivo, tumor lysates were prepared from vehicle-treated and RRD-251–treated mice and Rb–Raf-1 interaction was assessed by immunoprecipitation–Western blots. As shown in Fig. 2C, tumors from vehicle-treated mice showed robust Rb–Raf-1 interaction whereas RRD-251 treatment reduced the Rb–Raf-1 interaction in SK-MEL-28 xenografts. This shows that the drug is affecting the intended target in vivo.

**Induction of apoptosis and cell-cycle arrest in melanoma cells by RRD-251**

To elucidate the molecular mechanisms behind the anticancer property of RRD-251, we next determined its ability to induce cell-cycle arrest and/or apoptosis in melanoma cells. First, SK-MEL-28 and SK-MEL-5 cells were treated with 50 μmol/L of RRD-251 for 18 hours and TUNEL staining was done. RRD-251 treatment induced apoptosis in both cell lines as shown by a 30% to 40% increase in TUNEL-positive cells as compared with DMSO-treated control cells (Fig. 3A, left panel). Because there was induction of apoptosis by RRD-251, we evaluated whether the level of E2F1 was affected by RRD-251 treatment. It was found that RRD-251 inhibited Rb hyperphosphorylation and decreased the levels of E2F1 after 4 hours treatment in SK-MEL-28, SK-MEL-5, and SK-MEL-2 cells (Fig. 3A, right panel). The induction of apoptosis was further verified by examining the induction of caspase-3 and PARP cleavage. Toward this purpose, SK-MEL-28, SK-MEL-5, and SK-MEL-2 cells were treated with 50 μmol/L of RRD-251; whole cell lysates were prepared at different time intervals and Western blotting was done to detect the presence of cleaved caspase-3 and PARP. The cleaved band of caspase-3 and PARP was detected as early as 4 hours after RRD-251 treatment in all the 3 cell lines (Fig. 3B, left panel). Induction of PARP cleavage by RRD-251 was observed in 8 additional melanoma cell lines, including 2 carrying a wild-type B-Raf gene (data not shown). The involvement of caspases in RRD-251–induced apoptosis was next tested, using the pan-caspase inhibitor Z-VAD. Cells were pretreated with 20 μmol/L of Z-VAD for 30 minutes, following which the cells were treated with RRD-251 for 8 hours. The induction of apoptosis was monitored by the detection of PARP cleavage. As can be seen in Fig. 3B (right panel), pan-caspase inhibitor Z-VAD completely suppressed
RRD-251 induced apoptosis as indicated by the absence of PARP cleavage in all the 3 cell lines. Because decrease in E2F1 levels (Fig. 3A) should result in cell-cycle perturbations, we next assessed how RRD-251 treatment alters cell-cycle progression in these melanoma cells. Cells were treated with 20 μmol/L and 50 μmol/L of RRD-251 for 18 hours and cell-cycle distribution was evaluated by flow cytometry. As shown in Fig. 3C and D, RRD-251 treatment resulted in a dose-dependent inhibition of cell-cycle progression in SK-MEL-28 and SK-MEL-5 cells, respectively. Treatment with 50 μmol/L of RRD-251 increased the G0-G1 population from an average of 68% in untreated cells to 89% in SK-MEL-28 cells and from 72% to 86% in SK-MEL-5 cells after 18 hours. A concomitant decrease in S-phase population was observed, from an average of 23% to 2% and 22% to 6% in SK-MEL-28 and SK-MEL-5 cells, respectively. Interestingly, data showed that RRD-251 induces apoptosis at the same dose where we also observe reduction of E2F1 levels and cell-cycle rearrangement in melanoma cells.

**RRD-251 alters the expression of cell-cycle and apoptosis regulatory protein**

Further studies were done to evaluate the expression of E2F1 transcriptional targets involved in cell-cycle progression in response to RRD-251 treatment. E2F1 regulates G1-S phase transition through transcriptional regulation of a variety of genes such as cdc6 and Ts involved in DNA synthesis and replication. To examine how the expression of these genes is affected by RRD-251, we checked the mRNA levels of cdc6 and Ts in response to RRD-251 treatment by quantitative real-time PCR. Results revealed a reduction in the transcript levels of these genes when SK-MEL-28 and SK-MEL-5 cells were treated with 20 and 50 μmol/L of RRD-251 (Fig. 4A and B).

Earlier studies have reported that the overexpression of antiapoptotic proteins such as Bcl-2 and Mcl-1 in melanoma cells is associated with their progression (25–29). Because expression of many of the Bcl-2 family members are regulated through the Rb-E2F pathway, we next examined the expression of Bcl-2 family members, Bax and Mcl-1, in response to RRD-251 treatment. RRD-251 significantly downregulated the mRNA levels of the prosurvival protein Mcl-1 in SK-MEL-28, SK-MEL-5, and SK-MEL-2 cells after 4 hours of treatment (Fig. 4C). Decrease in mRNA expression resulted in decreased level of Mcl-1 protein also in all the 3 cell lines (Fig. 4D). In addition to changes in Mcl-1 expression, SK-MEL-28 cells also showed increased expression of the proapoptotic protein Bax, whereas Bcl-2 expression was not affected. SK-MEL-5 and SK-MEL-2 cells did not show any change in the expression of Bax or Bcl-2 in RRD-251–treated cells (data not shown). Collectively, these results suggest that RRD-251 treatment modulates the expression of vital genes involved in the regulation of the cell cycle and apoptosis, facilitating its anticancer effects.

**DTIC enhances the efficacy of RRD-251**

As mentioned earlier, DTIC is the most commonly used chemotherapeutic agent for the treatment of advanced melanoma but the response rate of melanoma to this conventional agent is low (3). Many studies have tried to explore different DTIC-based combinations to improve its clinical efficacy, but have failed to obtain better clinical response and overall survival (4, 5). Here we evaluated whether a combination of DTIC and RRD-251 had an enhanced effect on metastatic melanoma cells lines. Being an alkalyting agent, DTIC induces DNA damage to exert its physiologic effects as an anticancer drug (30). We examined the effect of DTIC on its ability to induce...
apoptosis or cell-cycle arrest in SK-MEL-28, SK-MEL-5, and SK-MEL-2 cells. Cells treated with DTIC at 50 μmol/L concentration for 48 hours failed to induce apoptosis in SK-MEL-5 and SK-MEL-28 cell lines, whereas SK-MEL-2 cells showed sensitivity against DTIC treatment (data not shown and see following sections). We next examined how DTIC affects the cell-cycle distribution of melanoma cells under similar conditions of treatment, using flow cytometry. Representative cell-cycle profile of SK-MEL-28 and SK-MEL-5 cells are given in Fig. 5A and B, respectively. Treatment with DTIC for 48 hours resulted in an increase in G0-G1 phase cells with a partial decrease in S and G2-M phase cells in both cell lines. This data suggests that DTIC, despite being a prodrug, has a certain amount of cell-cycle regulatory effects on melanoma cells in culture. Because SK-MEL-2 cells were sensitive to DTIC, we did not do cell-cycle analysis of this cell line.

Further, the effect of DTIC on DNA-damage was checked by comet assay. Cells were treated with DTIC
for 48 hours at 50 \( \mu \text{mol/L} \) concentration. The representative pictures of each cell line are shown in Fig. 5C. All the 3 cell lines showed mild to moderate DNA-damage with the tail length of approximately 1 or 2 times to the diameter of the head. The scored DNA-damage accounted the mean of approximately 25% in SK-MEL-5 and SK-MEL-28 and approximately 40% in SK-MEL-2 cells. Untreated cells had no DNA damage in any cell type (Fig. 5D).

Because DTIC failed to induce apoptosis as a single agent in SK-MEL-28 and SK-MEL-5 cell lines, we next evaluated its ability to interact with RRD-251-induced apoptosis in all the 3 cell lines. SK-MEL-2, SK-MEL-5, and SK-MEL-28 cells were pretreated with 50 \( \mu \text{mol/L} \) DTIC for 48 hours before treatment with RRD-251 for a period of 4 hours. The induction of apoptosis was assessed by detecting caspase-3 as well as PARP cleavage by Western blotting. As mentioned earlier, treatment with DTIC alone caused apoptosis in SK-MEL-2 cells as detected by decrease in caspase-3 and PARP cleavage (Fig. 6A; DTIC lane). Under similar conditions DTIC did not induce any apoptotic effect in SK-MEL-5 and SK-MEL-28 cell lines (Fig. 6B and C; DTIC lane). At the same time, pretreatment of DTIC resulted in increased apoptosis (DTIC + RRD-251 lane) as compared with RRD-251 alone as indicated by the detection of enhanced cleavage of PARP and caspase-3 in all the 3 cell lines. It is also important to note that treatment of DTIC and RRD-251 together for 4 hours did not result in increased apoptosis as compared with RRD-251 treatment alone (data not shown). Overall, data suggest that DTIC pretreatment can enhance the apoptotic potential of RRD-251 in melanoma cells.

DTIC-mediated enhanced efficacy of RRD-251 was further assessed by quantifying the levels of active caspase-3/7 using a luminescent-based assay. As shown in right panels of Fig. 6B and C, both the cell lines did not show any increased caspase activity after treatment with
DTIC for 48 hours, treatment with RRD-251 alone resulted in an average increase of caspase activity by 5 ± 1-fold in SK-MEL-28 and 2 ± 0.1-fold in SK-MEL-5 cells as compared with untreated cells. When the cells were pretreated with DTIC for 48 hours prior to RRD-251 treatment for 4 hours, both the cell lines showed a statistically significant increase in caspase activity (P < 0.05) as compared with RRD-251 treatment alone.

Figure 5. DTIC partially inhibits the cell-cycle progression. SK-MEL-28 (A) and SK-MEL-5 (B) cells were treated with 50 μmol/L dose of DTIC for 48 hours and subjected to flow cytometry analysis. The representative cell-cycle profile is shown. Histograms on the right represent the percentage of cells in the different phases of the cell cycle from 3 independent experiments. C, damaged DNA was visualized by the comet assay in SK-MEL-5, SK-MEL-28, and SK-MEL-2 cells following exposure to 50 μmol/L of DTIC for 48 hours. Representative micrograph of fluorescent DNA stain of control cells showing undamaged DNA remaining, whereas DTIC-treated cells show denatured DNA fragments migrating out from cell. D, %DNA damage was quantified and mean is represented with SD as error bars.
Figure 6. DTIC enhances the efficacy of RRD-251. A, SK-MEL-2 cells were pretreated with 50 μmol/L of DTIC for 48 hours before the exposure to RRD-251 for further 4 hours. Apoptosis was detected by the appearance of decreased caspase-3 and cleavage of PARP by Western blot analysis. DTIC as well as RRD-251 alone resulted in apoptosis. SK-MEL-28 (B, left) and SK-MEL-5 (C, left) cells were pretreated with 50 μmol/L of DTIC for 48 hours before the exposure to RRD-251 for further 4 hours. Apoptosis was detected by the appearance of cleaved caspase-3 and PARP by Western blot analysis. DTIC alone did not result in apoptosis (DTIC-lane). Pretreatment of DTIC before RRD-251 addition resulted in increased apoptosis as compared with RRD-251 treatment alone (DTIC + RRD-251-lane versus RRD-251-lane) in both the cells. B and C (right), the caspase-3 activity was quantified using Caspase Glo 3/7 kit in SK-MEL-28 and SK-MEL-5 cells. The pretreatment of DTIC before RRD-251 exposure resulted in significantly higher \((p < 0.05)\) caspase activity than these treatments alone in both the cell lines.
Overall, these results strongly suggested that DTIC pre-treatment enhances the apoptotic effect of RRD-251 in melanoma cells.

Discussion

Incidence of melanoma has been increasing at an alarming rate with very limited treatment choices and low overall disease-free survival. The fact that hyper-phosphorylation of Rb and its subsequent aberrant E2F activation are associated with melanoma progression and poor prognosis prompted us to evaluate the anti-tumor efficacy of the Rb-Raf-1 interaction disruptor RRD-251 in melanoma. Our studies show that RRD-251 disturbed cell-cycle progression and apoptosis signaling pathways, inhibited anchorage-dependent and -independent cell growth and suppress melanoma tumor growth in vivo. Many reports have shown that the tumor-suppressor function of Rb is deregulated at multiple levels in melanoma (10, 12, 13). Rb and its homologues, p107 and p130, are highly expressed in melanoma cells as compared with normal melanocytes and are inactivated by phosphorylation through the persistent CDKs activity (11, 13). Because Rb is rarely disabled by mutation in melanoma cells, novel approaches can be devised to reactivate its tumor suppressive functions. Recently, flavopiridol, a potent inhibitor of CDKs 1, 2, 4, and 7 activity was used in 1 of such approaches. Flavopiridol is shown to inhibit the progression of cell cycle and induction of apoptosis in melanoma cells (12), but failed to improve the status of melanoma patients at clinical level (31). Whereas CDKs phosphorylate Rb in mid to late G1 phase (32–34), our lab has shown that Raf-1 kinase binds and phosphorylates Rb early in the G1 phase (19). Disruption of this Rb–Raf-1 interaction by an 8-amino acid peptide (corresponding to Raf-1 residues 10–18) prevented Rb phosphorylation even in the late-G1 phase, suggesting that the binding of Raf-1 is necessary for the eventual phosphorylation and complete inhibition of Rb by CDKs (20). In addition, our results also showed that inhibition of Rb–Raf-1 interaction by RRD-251 could also suppress the proliferation of cells harboring mutations in the Rb regulatory pathway genes such as Ras, PTEN, p16INK4, as well as receptor tyrosine kinases (21). However, whether RRD-251 can suppress proliferation of tumor cells harboring mutations relevant to melanoma is not known. For example, oncogenic V600E mutation in B-Raf is prevalent in approximately 63% of melanoma tumor (35). Interestingly, here we show that RRD-251 was able to inhibit Rb phosphorylation even in melanoma cells that harbor the V600E mutation. We had observed earlier that whereas B-Raf could associate with Rb in cells, this interaction did not appear to have any significant regulatory effect on Rb function and RRD-251 could not disrupt the Rb-B-Raf interaction (20, 21). Melanoma cell lines with and without V600E mutation were sensitive to RRD-251 antiproliferative and proapoptotic effects. Furthermore, treatment of female nu/nu mice bearing SK-MEL-28 (V600E positive) xenograft tumors with 50 mg of RRD-251/kg of body weight resulted in a highly significant (p = 0.003) decrease in tumor growth. Taken together, these results provide evidences for the development of RRD-251 as a potential agent against metastatic melanoma.

Inhibition of apoptosis is the major molecular event associated with melanoma resistance against chemotherapy (25). Our results show that RRD-251 induces apoptosis in melanoma cells, as evident by TUNEL staining, activation of caspase-3 and cleavage of PARP. Recent studies have suggested that expression of antiapoptotic Mcl-1 protein expression is critically associated with inhibition of apoptosis in melanoma (25, 36). Here we show that melanoma cells treated with RRD-251 resulted in decreased expression of Mcl-1 at both transcriptional and translational levels. In addition, SK-MEL-28 cells also showed an increased expression of proapoptotic protein Bax in RRD-251–treated melanoma cells. Moreover, in addition to the induction of apoptosis we also found that RRD-251 blocks the S-phase entry of the cells. Data suggested that in addition to decrease in Rb phosphorylation, RRD-251 treatment downregulated the expression of E2F1 and its downstream cell-cycle regulatory genes T5 and cdc6 in melanoma cells. This occurs possibly through the degradation of the E2F1 protein rather than a transcriptional effect, given the fast kinetics of the reduction in E2F1 protein. It has been shown that E2F family members such as E2F1 and E2F6, are deregulated in melanoma and provide growth advantage to the cells (37). Therefore, as shown here, the ability of RRD-251 to downregulate E2F1 and its downstream target genes cdc6 and T5 highlights the importance of the potential use of RRD-251 in controlling the cell-cycle progression in melanoma cells.

DTIC either as a single agent, or as in combination with 2 or 3 drugs has failed to show any advantage in terms of response or survival of melanoma patients (38, 39). Results illustrated here suggest that DTIC has a mild to moderate DNA damage effect as well as partial effect on cell-cycle distribution in SK-MEL-28 and SK-MEL-5 cells; however, these cells were completely resistant for the induction of apoptosis for up to 48 hours at 50 μmol/L concentration. This is in accordance with the earlier studies from other groups who have also shown the resistance of SK-MEL-28 cells against DTIC treatment (40, 41). Interestingly, results from our study showed that cells pretreated with DTIC resulted in a statistically significant enhancement of the ability of RRD-251 to induce caspase activity and apoptosis. At the same time, because DTIC alone had no proapoptotic activity, it was synergistically enhanced by RRD-251 treatment in SK-MEL-5 and SK-MEL-28 cells. Notably, these results suggest that after DTIC exposure, DTIC-sensitive SK-MEL-2 as well as DTIC-resistant melanoma cells such as SK-MEL-28 and SK-MEL-5 cells show better sensitivity toward RRD-251–induced apoptosis. Thus,
this combination may be promising for the treatment of cancer patients with DTIC-resistant melanoma.

In conclusion, this work shows that RRD-251 has potent antitumoral activity against metastatic melanoma in vitro and in vivo. Results indicate that the decrease in Rb phosphorylation, downregulation of E2F1 and its downstream cell-cycle regulators such as TS and cdc6 as well as decrease in antiprotocytic protein McI-1 and upregulation of proapoptotic protein Bax may be involved in RRD-251–induced dual effects with cell-cycle arrest as well as induction of apoptosis. Furthermore, we show that the induction of apoptosis in melanoma cell lines was significantly enhanced by the combined treatment of DTIC and RRD-251 as compared with either treatment used alone. Overall, these results provide a rationale for the clinical evaluation of RRD-251 in combination with DTIC in advanced melanoma patients. Further elucidation of the apoptotic pathways and in vivo studies will aid in the effective implementation of this combination-based therapy against metastatic melanoma.

Disclosure of Potential Conflicts of Interest

The authors have no conflicts of interest to disclose.

Acknowledgments

We thank Michael Damit for technical assistance. Support from the Core Facilities at Moffitt Cancer Center is acknowledged.

Grant Support

This study was supported by the Donald Adams Comprehensive Melanoma Center as well as the Grant CA118210 from the NCI (S. Chellappan, S. Sebti, N. Lawrence).

Received 05/19/2010; revised 10/05/2010; accepted 10/19/2010; published OnlineFirst 12/07/2010.

References

1. Oliveria S, Dusza S, Berwick M. Issues in the epidemiology of mel-


7. Eberle J, Kurbanov BM, Hossini AM, Trefzer U, Fecker LF. Over-

expression of proapoptotic protein Bax may be involved in RRD-251–

induced dual effects with cell-cycle arrest as well as induction of apoptosis. Furthermore, we show that the induction of apoptosis in melanoma cell lines was significantly enhanced by the combined treatment of DTIC and RRD-251 as compared with either treatment used alone. Overall, these results provide a rationale for the clinical evaluation of RRD-251 in combination with DTIC in advanced melanoma patients. Further elucidation of the apoptotic pathways and in vivo studies will aid in the effective implementation of this combination-based therapy against metastatic melanoma.

Disclosure of Potential Conflicts of Interest

The authors have no conflicts of interest to disclose.

Acknowledgments

We thank Michael Damit for technical assistance. Support from the Core Facilities at Moffitt Cancer Center is acknowledged.

Grant Support

This study was supported by the Donald Adams Comprehensive Melanoma Center as well as the Grant CA118210 from the NCI (S. Chellappan, S. Sebti, N. Lawrence).

Received 05/19/2010; revised 10/05/2010; accepted 10/19/2010; published OnlineFirst 12/07/2010.

References

1. Oliveria S, Dusza S, Berwick M. Issues in the epidemiology of mel-


7. Eberle J, Kurbanov BM, Hossini AM, Trefzer U, Fecker LF. Over-

expression of proapoptotic protein Bax may be involved in RRD-251–

induced dual effects with cell-cycle arrest as well as induction of apoptosis. Furthermore, we show that the induction of apoptosis in melanoma cell lines was significantly enhanced by the combined treatment of DTIC and RRD-251 as compared with either treatment used alone. Overall, these results provide a rationale for the clinical evaluation of RRD-251 in combination with DTIC in advanced melanoma patients. Further elucidation of the apoptotic pathways and in vivo studies will aid in the effective implementation of this combination-based therapy against metastatic melanoma.

Disclosure of Potential Conflicts of Interest

The authors have no conflicts of interest to disclose.

Acknowledgments

We thank Michael Damit for technical assistance. Support from the Core Facilities at Moffitt Cancer Center is acknowledged.

Grant Support

This study was supported by the Donald Adams Comprehensive Melanoma Center as well as the Grant CA118210 from the NCI (S. Chellappan, S. Sebti, N. Lawrence).

Received 05/19/2010; revised 10/05/2010; accepted 10/19/2010; published OnlineFirst 12/07/2010.


Molecular Cancer Therapeutics

Rb–Raf-1 Interaction Disruptor RRD-251 Induces Apoptosis in Metastatic Melanoma Cells and Synergizes with Dacarbazine

Sandeep Singh, Rebecca Davis, Vignesh Alamanda, et al.

Mol Cancer Ther Published OnlineFirst December 7, 2010.

Updated version Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-10-0442

E-mail alerts Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.